Navigation Links
Growth factor regenerates tooth supporting structures: Results of a large randomized clinical trial
Date:11/8/2010

Alexandria, Va., USA It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.

In an article titled "FGF-2 Stimulates Periodontal Regeneration: Results of a Multicenter Randomized Clinical Trial," which is published in the International and American Associations for Dental Research's Journal of Dental Research, M. Kitamura, from Osaka University Graduate School of Dentistry, Japan, and a team of researchers conducted a human clinical trial to determine the safety and effectiveness of fibroblast growth factor-2 (FGF-2) for clinical application. This is the largest study to date in the field of periodontal regenerative therapy.

A randomized, double-masked, placebo-controlled clinical trial was conducted in 253 adults afflicted with periodontitis. Periodontal surgery was performed, during which one of three different doses of FGF-2 was randomly administered to localized bone defects. Each dose of FGF-2 showed significant superiority over the standard of care (vehicle alone (p < 0.01)) for the percentage of bone fill at 36 wks after administration, and the percentage peaked in the mid-dose FGF-2 group. These results strongly support the topical application of FGF-2 can be efficacious in the regeneration of human periodontal tissue that has been destroyed by periodontitis.

"This study represents the largest multi-center human clinical trial using growth factor therapy to repair tooth-supporting osseous defects," said JDR Editor-in-Chief William Giannobile. "The tissue engineering technology has important ramifications in the treating of localized bone defects around teeth resulting from periodontal disease."

The abstract is published in the Journal of Dental Research and is available online at http://bit.ly/jdr4616.

An accompanying editorial titled "Growth Factors and Periodontal Engineering: Where Next?" has been published. In it, author Martha Somerman, University of Washington, Seattle, states "for periodontal regeneration to continue as an attractive approach for restoring tissues lost to disease versus the choice for extraction and implant placement, we must focus our efforts on developing predictable therapies that include substantial restoration of tissues to physiological health with positive outcomes over the long term (e.g., greater than 10 years), as well as containing costs for our patients." To read this editorial, log in to the online JDR at http://bit.ly/jdr2203 or contact Ingrid L. Thomas at ithomas@iadr.org for a PDF of the article.


'/>"/>

Contact: Ingrid L. Thomas
ithomas@iadr.org
703-299-8084
International & American Association for Dental Research
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Researchers create drug to keep tumor growth switched off
3. Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009
4. Kaiser Analysis Finds Record Medicaid Enrollment Growth in 2009
5. Media, small businesses invited to ACS Webinar on ways to take advantage of Chinas dynamic growth
6. Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms
7. Mayo Clinic researchers find oncogene is important in pancreatic cancer growth and spread
8. Bitter melon extract decreased breast cancer cell growth
9. A mothers sensitivity may help language growth in children with autism spectrum disorder
10. Chitosan as alternative to growth-promoting antibiotics for ruminants
11. Buy HGH Website Educates Consumers on the Pros and Cons of Human Growth Hormone Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: